Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation

Rachel Thijssen, Gregor van Bochove, Martin FM de Rooij, Johanna ter Burg, Marcel Spaargaren, PhD, Coumaran Egile, PhD, Marie Jose Kersten, MD PhD, Eric Eldering, PhD, Arnon P. Kater, MD PhD

Blood (2014) 124 (21): 4691.

https://doi.org/10.1182/blood.V124.21.4691.4691

Published: 2014

Journal Articles

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

Jennifer R. Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Coumaran Egile, PhD, Rodrigo Ruiz-Soto, MD, MSc, Farrukh Awan, MD, MS

Blood (2013) 122 (21): 4170.

https://doi.org/10.1182/blood.V122.21.4170.4170

Published: 2013

Journal Articles

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Kyriakos P Papadopoulos, MD, Pau Abrisqueta, MD, Glenda Chambers, BSN, RN, OCN, CCRC, Drew Rasco, MD, Amita Patnaik, Josep Tabernero, MD, Kanya Rajangam, MD, PhD, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Julie M Vose, MD

Blood (2011) 118 (21): 1608.

https://doi.org/10.1182/blood.V118.21.1608.1608

Published: 2011

Journal Articles

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Jennifer R Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Arthur P. DeCillis, MD, MS, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 2683.

https://doi.org/10.1182/blood.V118.21.2683.2683

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation

Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only